arotinolol has been researched along with Hypertension in 14 studies
arotinolol: structure given in first source; arotinolol is the (+-)-isomer
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Arotinolol hydrochloride with alpha-and beta-receptor blocking action, developed in Japan, is mainly used for the treatment of hypertension." | 9.09 | [Clinical effect of arotinolol hydrochloride and its influence on renal function in elderly patients with essential hypertension]. ( Hattori, H; Hoshino, T; Iwai, K; Kawanishi, K; Kimura, Y; Matsumoto, M; Miyauchi, E; Munehira, J; Murai, H; Takasaki, M; Tsuchiya, H; Tsukio, Y; Yamada, K, 1999) |
| "To compare the effects of an alpha, beta blocker, arotinolol, in the treatment of essential hypertension between patients with a dipper and those with a non-dipper profile by means of 24-h ambulatory blood pressure monitoring (ABPM), a multicenter single blind parallel trial was carried out in five clinical centers." | 9.09 | Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers. ( Huang, J; Liu, G; Sun, N; Wu, H; Yu, Z; Zhang, Y; Zhou, Y, 2001) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 6.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Arotinolol hydrochloride with alpha-and beta-receptor blocking action, developed in Japan, is mainly used for the treatment of hypertension." | 5.09 | [Clinical effect of arotinolol hydrochloride and its influence on renal function in elderly patients with essential hypertension]. ( Hattori, H; Hoshino, T; Iwai, K; Kawanishi, K; Kimura, Y; Matsumoto, M; Miyauchi, E; Munehira, J; Murai, H; Takasaki, M; Tsuchiya, H; Tsukio, Y; Yamada, K, 1999) |
| "To compare the effects of an alpha, beta blocker, arotinolol, in the treatment of essential hypertension between patients with a dipper and those with a non-dipper profile by means of 24-h ambulatory blood pressure monitoring (ABPM), a multicenter single blind parallel trial was carried out in five clinical centers." | 5.09 | Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers. ( Huang, J; Liu, G; Sun, N; Wu, H; Yu, Z; Zhang, Y; Zhou, Y, 2001) |
| "To evaluate the preventive effect of nitrate tolerance, 24 patients with untreated hypertension were randomized to receive either carvedilol (10 mg twice a day [carvedilol group, n=8]), arotinolol (10 mg twice a day [arotinolol group, n=8]), or placebo (placebo group, n=8)." | 5.08 | Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 2.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Amosulalol was approximately threefold more potent than labetalol and arotinolol in decreasing blood pressure (BP) in conscious SHR." | 1.29 | Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats. ( Honda, K; Inagaki, O; Nakagawa, C; Shibasaki, M; Sudoh, K, 1994) |
| " At dosage levels similar to arotinolol, both pindolol and labetalol were less effective in preventing cerebral lesions despite lower blood pressure." | 1.28 | Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP. ( Hara, Y; Maniwa, T; Miyagishi, A; Noguchi, T, 1991) |
| "Arotinolol (S-596, ARL) is a beta-adrenoceptor blocking drug with weak alpha-adrenoceptor blocking activity, and may be classified into the fourth generation." | 1.27 | Chronic effects of arotinolol (S-596) in spontaneously hypertensive rats. ( Kawashima, K; Kishi, K; Saito, K; Sokabe, H, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 7 (50.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, H | 1 |
| Chen, W | 1 |
| Liu, X | 1 |
| Xu, W | 1 |
| Abe, M | 1 |
| Mori, K | 1 |
| Nagai, K | 1 |
| Ito, S | 1 |
| Hara, Y | 2 |
| Nakahara, H | 1 |
| Miyagishi, A | 2 |
| Nakatani, H | 1 |
| Takekoshi, N | 1 |
| Murakami, E | 1 |
| Matsui, S | 1 |
| Murakami, H | 1 |
| Emoto, J | 1 |
| Hashimoto, A | 1 |
| Harasawa, Y | 1 |
| Imaizumi, T | 1 |
| Ando, S | 1 |
| Masaki, H | 1 |
| Harada, S | 1 |
| Momohara, M | 1 |
| Takeshita, A | 1 |
| Inagaki, O | 1 |
| Sudoh, K | 1 |
| Shibasaki, M | 1 |
| Nakagawa, C | 1 |
| Honda, K | 1 |
| Sasaki, H | 1 |
| Naka, K | 1 |
| Kishi, Y | 1 |
| Ohoshi, T | 1 |
| Hagihara, T | 1 |
| Matsuo, H | 1 |
| Sowa, R | 1 |
| Matsumoto, G | 1 |
| Sanke, T | 1 |
| Nanjo, K | 1 |
| Kuwajima, I | 1 |
| Suzuki, Y | 1 |
| Otsuka, K | 1 |
| Kawamura, H | 1 |
| Kuramoto, K | 1 |
| Watanabe, H | 1 |
| Kakihana, M | 1 |
| Ohtsuka, S | 1 |
| Sugishita, Y | 1 |
| Miyauchi, E | 1 |
| Matsumoto, M | 1 |
| Kimura, Y | 1 |
| Hattori, H | 1 |
| Tsukio, Y | 1 |
| Tsuchiya, H | 1 |
| Takasaki, M | 1 |
| Munehira, J | 1 |
| Yamada, K | 1 |
| Iwai, K | 1 |
| Kawanishi, K | 1 |
| Hoshino, T | 1 |
| Murai, H | 1 |
| Wu, H | 1 |
| Zhang, Y | 2 |
| Huang, J | 1 |
| Liu, G | 1 |
| Sun, N | 1 |
| Yu, Z | 1 |
| Zhou, Y | 1 |
| Maniwa, T | 1 |
| Noguchi, T | 1 |
| Kishi, K | 1 |
| Kawashima, K | 1 |
| Sokabe, H | 1 |
| Saito, K | 1 |
| Morimoto, Y | 1 |
| Kasai, A | 1 |
| Nagano, K | 1 |
| Umino, M | 1 |
| Kakuta, Y | 1 |
| Iwata, J | 1 |
| Konishi, T | 1 |
| Hamada, M | 1 |
| Nakano, T | 1 |
4 trials available for arotinolol and Hypertension
| Article | Year |
|---|---|
The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Anti | 2014 |
Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol.
Topics: Adrenergic Antagonists; Adult; Aged; Blood Flow Velocity; Blood Platelets; Blood Pressure; Carbazole | 1998 |
[Clinical effect of arotinolol hydrochloride and its influence on renal function in elderly patients with essential hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive | 1999 |
Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian | 2001 |
10 other studies available for arotinolol and Hypertension
| Article | Year |
|---|---|
Relapse of Graves' disease in a patient with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antithyroid Agen | 2003 |
[Antihypertensive effect of arotinolol (S-596), a new adrenergic beta blocking agent, on experimental hypertension].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Heart Rate; Hypertension; Male; Propanol | 1983 |
Studies on concurrent alpha- and beta-adrenoceptor blocking action of S-596 (arotinolol).
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Cardiac Outp | 1983 |
Influence of arotinolol hydrochloride on heart rate spectrum in hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertensi | 1994 |
Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypert | 1994 |
Nicardipine may impair glucose metabolism in hypertensive diabetic patients.
Topics: Adult; Aged; Atenolol; Carteolol; Diabetes Mellitus, Type 2; Diltiazem; Enalapril; Female; Glucose; | 1994 |
Effects of alpha,beta-blocker, arotinolol chloride, on 24-h blood pressure--difference between elderly and younger hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Blood Pressure; Blood Pressure Determination; | 1993 |
Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Brain; Cerebrovascular Disorders; Disease Susc | 1991 |
Chronic effects of arotinolol (S-596) in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Blood Pressure; Body Weight; Heart Rate; Hyperten | 1985 |
[Effects of arotinolol hydrochloride on hemodynamics, catecholamine levels and metabolism in patients with essential hypertension].
Topics: Adrenergic beta-Antagonists; Aged; Catecholamines; Female; Hemodynamics; Humans; Hypertension; Male; | 1988 |